Universe Pharmaceuticals annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Universe Pharmaceuticals R&D Spending Growth & History (UPC)
Universe Pharmaceuticals's r&d spending was $671.8M for fiscal 2025.
View full Universe Pharmaceuticals company overviewUniverse Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $671.8M | −$2.36B | −77.84% |
| 2024 | 2024-09-30 | $3.03B | $3.03B | +62287.26% |
| 2023 | 2023-09-30 | $4.9M | −$2.8M | −36.44% |
| 2022 | 2022-09-30 | $7.6M | $2.2M | +39.86% |
| 2021 | 2021-09-30 | $5.5M | $4.9M | +837.31% |
| 2020 | 2020-09-30 | $583,125 | −$35,312 | −5.71% |
| 2019 | 2019-09-30 | $618,437 | — | — |
Universe Pharmaceuticals r&d spending trends
Over the last five fiscal years, Universe Pharmaceuticals's r&d spending increased from $583,125 to $671.8M, a change of $671.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Universe Pharmaceuticals source filings ↗